ACADIA Pharmaceuticals Inc
NASDAQ:ACAD

Watchlist Manager
ACADIA Pharmaceuticals Inc Logo
ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
Watchlist
Price: 16.37 USD 1.17% Market Closed
Market Cap: 2.7B USD
Have any thoughts about
ACADIA Pharmaceuticals Inc?
Write Note

ACADIA Pharmaceuticals Inc
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ACADIA Pharmaceuticals Inc
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
Interest Income Expense
$23.2m
CAGR 3-Years
185%
CAGR 5-Years
20%
CAGR 10-Years
44%
Abbvie Inc
NYSE:ABBV
Interest Income Expense
-$2B
CAGR 3-Years
7%
CAGR 5-Years
-9%
CAGR 10-Years
-13%
Gilead Sciences Inc
NASDAQ:GILD
Interest Income Expense
-$948m
CAGR 3-Years
26%
CAGR 5-Years
-6%
CAGR 10-Years
-10%
Amgen Inc
NASDAQ:AMGN
Interest Income Expense
-$2.4B
CAGR 3-Years
-34%
CAGR 5-Years
-29%
CAGR 10-Years
-15%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Interest Income Expense
$598m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Interest Income Expense
$990m
CAGR 3-Years
23%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

ACADIA Pharmaceuticals Inc
Glance View

Market Cap
2.7B USD
Industry
Biotechnology

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 514 full-time employees. The company went IPO on 2004-05-27. The Company’s pipeline product candidates in CNS areas includes NUPLAZID (pimavanser), Trofinetide, ACP-044 and ACP-319. NUPLAZID (pimavanserin) is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). ACP-044, is an orally administered, non-opioid analgesic being evaluated for the treatment of pain. The firm has initiated a Phase II study evaluating ACP-044 for the treatment of postoperative pain following bunionectomy surgery. The firm also initiated an additional Phase II study evaluating ACP-044 for the treatment of pain associated with osteoarthritis. ACP-319 is a positive allosteric modulator of the muscarinic receptor targeting M1 (M1 PAM).

ACAD Intrinsic Value
19.77 USD
Undervaluation 17%
Intrinsic Value
Price

See Also

What is ACADIA Pharmaceuticals Inc's Interest Income Expense?
Interest Income Expense
23.2m USD

Based on the financial report for Sep 30, 2024, ACADIA Pharmaceuticals Inc's Interest Income Expense amounts to 23.2m USD.

What is ACADIA Pharmaceuticals Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
44%

Over the last year, the Interest Income Expense growth was 44%. The average annual Interest Income Expense growth rates for ACADIA Pharmaceuticals Inc have been 185% over the past three years , 20% over the past five years , and 44% over the past ten years .

Back to Top